155 related articles for article (PubMed ID: 33573148)
1. Susceptibility Testing Is Key for the Success of Cefiderocol Treatment: A Retrospective Cohort Study.
Bleibtreu A; Dortet L; Bonnin RA; Wyplosz B; Sacleux SC; Mihaila L; Dupont H; Junot H; Bunel V; Grall N; Razazi K; Duran C; Tattevin P; Dinh A; The Cefiderocol French Study Group OBO
Microorganisms; 2021 Jan; 9(2):. PubMed ID: 33573148
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, Gram-negative bacteria.
Wang Y; Li Y; Zhao J; Guan J; Ni W; Gao Z
Ann Transl Med; 2022 Mar; 10(5):261. PubMed ID: 35402576
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of cefiderocol and other newly approved antimicrobials against multi-drug resistant Gram-negative pathogens recovered in intensive care units in Spain and Portugal.
Gijón D; García-Castillo J; Fernández-López MC; Bou G; Siller M; Calvo-Montes J; Pitart C; Vila J; Torno N; Gimeno C; Cruz H; Ramos H; Mulet X; Oliver A; Ruiz-Garbajosa P; Canton R
Rev Esp Quimioter; 2024 Feb; 37(1):69-77. PubMed ID: 37882320
[TBL] [Abstract][Full Text] [Related]
4. In Vitro Activity of Cefiderocol on Multiresistant Bacterial Strains and Genomic Analysis of Two Cefiderocol Resistant Strains.
Padovani M; Bertelli A; Corbellini S; Piccinelli G; Gurrieri F; De Francesco MA
Antibiotics (Basel); 2023 Apr; 12(4):. PubMed ID: 37107147
[TBL] [Abstract][Full Text] [Related]
5. In vitro Activity of Cefiderocol and Comparators against Carbapenem-Resistant Gram-Negative Pathogens from France and Belgium.
Oueslati S; Bogaerts P; Dortet L; Bernabeu S; Ben Lakhal H; Longshaw C; Glupczynski Y; Naas T
Antibiotics (Basel); 2022 Oct; 11(10):. PubMed ID: 36290010
[TBL] [Abstract][Full Text] [Related]
6. [Cefiderocol: a novel siderophore cephalosporin against multi-drug resistant Gram-negative bacilli infections].
Kuai J; Wang X; Wang H
Sheng Wu Gong Cheng Xue Bao; 2022 Mar; 38(3):990-1003. PubMed ID: 35355469
[TBL] [Abstract][Full Text] [Related]
7. Cefiderocol for Carbapenem-Resistant Bacteria: Handle with Care! A Review of the Real-World Evidence.
Sansone P; Giaccari LG; Coppolino F; Aurilio C; Barbarisi A; Passavanti MB; Pota V; Pace MC
Antibiotics (Basel); 2022 Jul; 11(7):. PubMed ID: 35884158
[TBL] [Abstract][Full Text] [Related]
8. Cefiderocol - An effective antimicrobial for MDR infections but a challenge for routine antimicrobial susceptibility testing.
Brauncajs M; Bielec F; Macieja A; Pastuszak-Lewandoska D
Adv Med Sci; 2024 May; 69(2):256-263. PubMed ID: 38782257
[TBL] [Abstract][Full Text] [Related]
9. Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence.
Wang C; Yang D; Wang Y; Ni W
Front Pharmacol; 2022; 13():896971. PubMed ID: 35496290
[TBL] [Abstract][Full Text] [Related]
10. An Overview of Cefiderocol's Therapeutic Potential and Underlying Resistance Mechanisms.
Domingues S; Lima T; Saavedra MJ; Da Silva GJ
Life (Basel); 2023 Jun; 13(7):. PubMed ID: 37511802
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy and safety of cefiderocol for resistant Gram-negative infections: a real-life, single-centre experience.
Karruli A; Massa A; Andini R; Marrazzo T; Ruocco G; Zampino R; Durante-Mangoni E
Int J Antimicrob Agents; 2023 Feb; 61(2):106723. PubMed ID: 36642233
[TBL] [Abstract][Full Text] [Related]
12. Cefiderocol is an effective topical monotherapy for experimental extensively-drug resistant
Romanowski EG; Mumper SM; Shanks HQ; Yates KA; Mandell JB; Zegans ME; Shanks RMQ
bioRxiv; 2023 Sep; ():. PubMed ID: 37693441
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of cefiderocol for off-label treatment indications: A systematic review.
Babidhan R; Lewis A; Atkins C; Jozefczyk NJ; Nemecek BD; Montepara CA; Gionfriddo MR; Zimmerman DE; Covvey JR; Guarascio AJ
Pharmacotherapy; 2022 Jul; 42(7):549-566. PubMed ID: 35611627
[TBL] [Abstract][Full Text] [Related]
14. Real-world experience with cefiderocol therapy for
Chou A; Ramsey D; Amenta E; Trautner BW
Antimicrob Steward Healthc Epidemiol; 2023; 3(1):e90. PubMed ID: 37179761
[TBL] [Abstract][Full Text] [Related]
15. Carbapenem-Resistant
Giannella M; Verardi S; Karas A; Abdel Hadi H; Dupont H; Soriano A; Santerre Henriksen A; Cooper A; Falcone M;
Open Forum Infect Dis; 2023 Jul; 10(7):ofad329. PubMed ID: 37496600
[TBL] [Abstract][Full Text] [Related]
16. Combating antimicrobial resistance with cefiderocol for complicated infections involving the urinary tract.
Wang H; Palasik BN
Ther Adv Urol; 2022; 14():17562872211065570. PubMed ID: 35126672
[TBL] [Abstract][Full Text] [Related]
17. Total and Unbound Pharmacokinetics of Cefiderocol in Critically Ill Patients.
Zahr N; Urien S; Llopis B; Noé G; Tissot N; Bihan K; Junot H; Marin C; Mansour B; Luyt CE; Bleibtreu A; Funck-Brentano C
Pharmaceutics; 2022 Dec; 14(12):. PubMed ID: 36559279
[TBL] [Abstract][Full Text] [Related]
18. Intravenous Fosfomycin: A Potential Good Partner for Cefiderocol. Clinical Experience and Considerations.
Marino A; Stracquadanio S; Campanella E; Munafò A; Gussio M; Ceccarelli M; Bernardini R; Nunnari G; Cacopardo B
Antibiotics (Basel); 2022 Dec; 12(1):. PubMed ID: 36671250
[TBL] [Abstract][Full Text] [Related]
19. Real-Life Data on the Effectiveness and Safety of Cefiderocol in Severely Infected Patients: A Case Series.
Fendian ÁM; Albanell-Fernández M; Tuset M; Pitart C; Castro P; Soy D; Bodro M; Soriano A; Del Río A; Martínez JA
Infect Dis Ther; 2023 Apr; 12(4):1205-1216. PubMed ID: 36943617
[TBL] [Abstract][Full Text] [Related]
20. Clinical Outcome of Cefiderocol for Infections with Carbapenem-Resistant Organisms.
Sajib MI; Monteforte M; Go R
Antibiotics (Basel); 2023 May; 12(5):. PubMed ID: 37237839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
